Published in Curr Opin Neurol on June 01, 2003
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Stem cell transplantation in multiple sclerosis. J Neurol (2008) 0.78
Aggressive multiple sclerosis-is there a role for stem cell transplantation? J Neurol (2005) 0.75
[Stem cell therapy in multiple sclerosis: a clinical update]. Z Rheumatol (2009) 0.75
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One (2012) 1.67
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet (2003) 1.59
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur J Immunol (2008) 1.51
Clinical nurse specialists and the practice of community nurses. J Adv Nurs (2006) 1.42
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol (2013) 1.29
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 1.22
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain (2010) 1.21
T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol (2012) 1.21
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol (2004) 1.15
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
The value of animal models for drug development in multiple sclerosis. Brain (2006) 1.11
Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol (2004) 1.07
Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol (2011) 1.07
Application of support vector machines for T-cell epitopes prediction. Bioinformatics (2003) 1.05
Infectious causes of multiple sclerosis. Lancet Neurol (2006) 1.04
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol (2012) 1.01
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. J Infect Dis (2006) 0.98
Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol (2008) 0.95
High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol (2007) 0.95
Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae. Am J Pathol (2007) 0.95
Spotlight on anti-CD25: daclizumab in MS. Int MS J (2008) 0.94
Training-dependent plasticity in patients with multiple sclerosis. Brain (2004) 0.94
Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis. Infect Immun (2006) 0.92
Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog (2005) 0.92
HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol (2005) 0.92
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol (2007) 0.91
Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol (2010) 0.91
Genomics in multiple sclerosis--current state and future directions. J Neuroimmunol (2007) 0.90
Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res (2013) 0.89
Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol (2013) 0.89
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol (2003) 0.89
Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol (2007) 0.89
Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression. J Neuropathol Exp Neurol (2006) 0.89
Antigen-specific therapies in MS - Current concepts and novel approaches. J Neurol Sci (2008) 0.88
Kinematic specificity of cortical reorganization associated with motor training. Neuroimage (2004) 0.88
Nogo receptor is involved in the adhesion of dendritic cells to myelin. J Neuroinflammation (2011) 0.87
T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol (2013) 0.87
Use of combinatorial peptide libraries for T-cell epitope mapping. Methods (2003) 0.87
TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection. J Immunol (2012) 0.86
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol (2005) 0.86
Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient. J Neurovirol (2002) 0.86
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. Glia (2005) 0.86
Autoantigens act as tissue-specific chemoattractants. J Leukoc Biol (2005) 0.85
Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treat Rev (2013) 0.85
Molecular mimicry in multiple sclerosis. Autoimmunity (2006) 0.85
Multiple sclerosis: closing in on an oral treatment. Nature (2010) 0.85
Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol (2006) 0.85
The immunopathogenesis of multiple sclerosis. J Rehabil Res Dev (2002) 0.85
Clinically isolated neurosarcoidosis: a recommended diagnostic path. Eur Neurol (2014) 0.83
Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med (2004) 0.83
Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis. J Neuroimmunol (2005) 0.82
Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. J Neuroimmunol (2013) 0.82
Antigen-specific therapies in multiple sclerosis. Int Rev Immunol (2005) 0.82
Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis. PLoS One (2011) 0.82
Antigen-specific tolerization approaches in multiple sclerosis. Expert Opin Investig Drugs (2013) 0.81
Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. Lancet Neurol (2008) 0.81
The initiation of the autoimmune response in multiple sclerosis. Clin Neurol Neurosurg (2004) 0.81
Findings on T cell specificity revealed by synthetic combinatorial libraries. J Immunol Methods (2002) 0.80
Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS One (2012) 0.80
HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain (2013) 0.80
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis. Mult Scler (2009) 0.79
T-cell epitope prediction with combinatorial peptide libraries. J Comput Biol (2002) 0.79
HLA class I: friend and foe of multiple sclerosis. Nat Med (2008) 0.79
Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol (2005) 0.79
Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones. J Immunol Methods (2009) 0.79
Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult Scler (2011) 0.78
Stem cell transplantation in multiple sclerosis. J Neurol (2008) 0.78
Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity (2013) 0.78
Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol (2012) 0.78
Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. J Neuroimmunol (2006) 0.77
Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling. Eur J Immunol (2014) 0.77
Limited repertoire of HLA-DRB1*0401-restricted MBP111-129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential. J Neuroimmunol (2004) 0.77
Displacement chromatography as first separating step in online two-dimensional liquid chromatography coupled to mass spectrometry analysis of a complex protein sample--the proteome of neutrophils. J Chromatogr A (2012) 0.76